-
EP3707165
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3707165
| EP3707165 - TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 17.05.2024 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 14.08.2020 | ||
| Former | The international publication has been made Status updated on 18.05.2019 | Most recent event Tooltip | 12.10.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states The Board of Regents of The University of Texas System 210 West 7th Street Austin, TX 78701 / US | [2020/38] | Inventor(s) | 01 /
ZHANG, Chengcheng 4501 Druid Lane Apt. 117 Dallas, TX 75205 / US | 02 /
JOHN, Samuel c/o UT Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390 / US | 03 /
CHEN, Heyu c/o UT Southwestern Medical Center 5323 Harry Hines Blvd Dallas, TX 75390 / US | 04 /
DENG, Mi 4712 Bull Run Drive Plano, TX 75093 / US | 05 /
GUI, Xun c/o UT Health Science Center at Houston 7000 Fannin Street Suite 720 Houston, TX 77030 / US | 06 /
ZHANG, Ningyan c/o UT Health Science Center at Houston 7000 Fannin Street Suite 720 Houston, TX 77030 / US | 07 /
AN, Zhiqiang c/o UT Health Science Center at Houston 7000 Fannin Street Suite 720 Houston, TX 77030 / US | [2020/38] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2020/38] | Potter Clarkson The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 18876416.1 | 06.11.2018 | [2020/38] | WO2018US59362 | Priority number, date | US201762582769P | 07.11.2017 Original published format: US 201762582769 P | US201762583825P | 09.11.2017 Original published format: US 201762583825 P | US201762584770P | 11.11.2017 Original published format: US 201762584770 P | [2020/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019094360 | Date: | 16.05.2019 | Language: | EN | [2019/20] | Type: | A1 Application with search report | No.: | EP3707165 | Date: | 16.09.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.05.2019 takes the place of the publication of the European patent application. | [2020/38] | Search report(s) | International search report - published on: | US | 16.05.2019 | (Supplementary) European search report - dispatched on: | EP | 06.08.2021 | Classification | IPC: | C07K16/28, A61K39/395, A61P35/02, G01N33/574, A61K35/17 | [2021/36] | CPC: |
A61P35/02 (EP,KR,US);
C07K16/2803 (EP,KR);
C07K14/70503 (US);
A61K2239/26 (EP,KR,US);
A61K2239/31 (EP,KR,US);
A61K2239/38 (EP,KR,US);
A61K39/4611 (EP,KR,US);
A61K39/4613 (EP,KR,US);
A61K39/4631 (EP,KR,US);
A61K39/464411 (EP,KR,US);
A61K45/06 (US);
C07K14/7051 (EP);
C12N15/00 (US);
C12N5/0636 (EP,KR,US);
C12N5/0646 (EP,KR,US);
A61K2039/505 (KR);
A61K2039/585 (KR);
A61K38/00 (EP,US);
C07K2317/24 (EP,KR);
C07K2317/622 (EP,KR);
C07K2317/76 (EP,KR);
|
| Former IPC [2020/38] | C07K16/28, A61K39/395, A61P35/02, G01N33/574 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/38] | Title | German: | LILRB4-TARGETING MIT CAR-T- ODER CAR-NK-ZELLEN BEI DER BEHANDLUNG VON KREBS | [2020/38] | English: | TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER | [2020/38] | French: | CIBLAGE DE LILRB4 AVEC DES CELLULES CAR-T OU CAR-NK DANS LE TRAITEMENT DU CANCER | [2020/38] | Entry into regional phase | 05.06.2020 | National basic fee paid | 05.06.2020 | Search fee paid | 05.06.2020 | Designation fee(s) paid | 05.06.2020 | Examination fee paid | Examination procedure | 05.06.2020 | Examination requested [2020/38] | 03.03.2022 | Amendment by applicant (claims and/or description) | 17.05.2024 | Despatch of a communication from the examining division (Time limit: M04) | 17.09.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 05.06.2020 | Renewal fee patent year 03 | 21.10.2021 | Renewal fee patent year 04 | 14.11.2022 | Renewal fee patent year 05 | 13.09.2023 | Renewal fee patent year 06 | 11.10.2024 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2016144728 (UNIV TEXAS [US]); | International search | [A]WO2009155723 (ESBATECH AN ALCON BIOMEDICAL R [CH], et al); | [YA]US2014271582 (FORMAN STEPHEN [US], et al); | [A]WO2016130726 (MINERVA BIOTECHNOLOGIES CORP [US]); | [YA]WO2016144728 (UNIV TEXAS [US]); | [A]WO2016207240 (HOFFMANN LA ROCHE [CH], et al); | [Y]US2017095531 (SCHREIBER TAYLOR [US], et al) | by applicant | US4870287 | WO9501994 | US5739169 | US5760395 | US5801005 | WO9842752 | US5824311 | US5830880 | US5844905 | US5846945 | US5885796 | WO0037504 | WO0114424 | US6207156 | US2005260186 | US2006104968 | WO2006121168 | WO2009101611 | WO2009114335 | WO2010027827 | US2011008369 | WO2011066342 | US8008449 | US8017114 | US8119129 | US8329867 | US8354509 | US2014022021 | US8735553 | US2014294898 |